Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $186.68M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.23M
Average 0.26M
Returns on capital
Cartesian Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
103.2%
avg 179.4%
ROIC
-28.4%
avg -54.0%
ROA
-44.0%
avg -48.8%
Analysis
ROE is currently the strongest return metric at 103.2% versus its period average of 179.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Peter G. Traber | Head of R&D | USD 2.76M | 71 | — | — |
Carsten Brunn | President, Chief Executive Officer & Chairman of the Board | USD 1.04M | 55 | 323.53K | 1.10% |
Blaine T. Davis | Chief Financial Officer | USD 693.35K | 52 | — | — |
Emily English | Chief Operating Officer | USD 589.81K | 46 | 71.00K | 0.24% |
Matthew Bartholomae | General Counsel & Secretary | — | — | — | — |
June Seymour | Chief Accounting Officer | — | 48 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$205,797.00
Sells
3
$258,671.22
Net Transaction Value
−$52,874.22
Net selling
Most Active
Brunn Carsten
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jan 6, 26Jan 6, 2026 | Brunn Carsten Direct | Sell | $162.1K$162,076.99 |
| Jan 6, 26Jan 6, 2026 | Miljkovic Milos Direct | Sell | $24.4K$24,366.79 |
| Jan 6, 26Jan 6, 2026 | Davis Blaine Direct | Sell | $72.2K$72,227.44 |
| Dec 4, 25Dec 4, 2025 | BARABE TIMOTHY C Direct | Buy | $205.8K$205,797.00 |
Summary
Insiders reported 1 buys worth $205,797.00 and 3 sells worth $258,671.22 over the last 12 months. That adds up to net selling of $52,874.22. Brunn Carsten was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -70.7% | +142.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -70.7% over three years. Forward estimates point to Revenue at +142.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Cartesian Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about RNAC's management, answered from reported figures.
Who manages RNAC?
Cartesian Therapeutics, Inc. (RNAC) lists 6 active executives. The top listed executive is Carsten Brunn, President, Chief Executive Officer & Chairman of the Board.
Are RNAC insiders buying or selling?
Recent insider activity shows net buying of $72.40M.
Continue the stock analysis
Jump to another research area for this company.